key: cord-1026724-dry3rckf authors: Ryan, Pablo; Pérez-García, Felipe; Torres-Macho, Juan; Bibiano, Carlos; Ignacio Lazo, Juan; Castaño-Ochoa, Guillermo; Vidal-Alcántara, Erick Joan; Muñoz-Gómez, María José; Martínez, Isidoro; Resino, Salvador title: Misdiagnosis rate of among negative COVID-19 patients in real-life with Panbio COVID-19 Antigen Rapid Test during 2021 date: 2022-03-16 journal: J Infect DOI: 10.1016/j.jinf.2022.03.013 sha: 9d9c78274a8192c19559d5765227d48b95af37b9 doc_id: 1026724 cord_uid: dry3rckf nan However, the sensitivity is usually higher when exposure to COVID-19 is suspected, or symptoms of COVID-19 are present (2) . Moreover, the probability that a positive or negative result was true varies with the prevalence and therefore influences the likelihood of misdiagnosis (3) . Focusing on the consequences of misdiagnosis is also necessary because it could help choose the most appropriate test. Diagnostic testing of SARS-CoV-2 is critical for the control of the pandemic. The RT-qPCR is the gold standard for diagnosing SARS-CoV-2 infection. However, this method takes a long time (several hours) and requires specialized equipment and trained personnel (4) . Besides, RT-PCR has a low detection limit but can detect SARS-CoV-2 RNA fragments that can be positive without evidence of active viral replication, overestimating the number of COVID-19 infectious patients. Rapid antigen detection tests (RADTs) are lateral flow immunoassays (LFA) that are frequently used as point of care (POC) tests for the detection of active SARS-CoV-2 infection. These tests are fast, reliable, inexpensive, and detect SARS-CoV-2 proteins in respiratory samples (4, 5) . The diagnostic performance of RADTs has been extensively evaluated (4, 6) , detecting most SARS-CoV-2 positive samples among individuals at high risk for SARS-CoV-2 infection (symptomatic or direct contact with a positive case). However, despite having high specificity, RADTs can report false negatives, giving a false sense of security that often leads to relaxing preventive measures, such as wearing masks indoors or in crowded places, maintaining social distancing, and ventilating closed spaces (5) . The diagnostic performance of the RADTs may change depending on symptoms and SARS-CoV-2 prevalence (3). It may also be influenced by the variant of SARS-CoV-2 and the vaccination status (7) . Therefore, the role of RADTs needs to be re-evaluated over time according to these parameters. The Panbio COVID-19 Antigen Rapid Test (Abbott Rapid Diagnostic Jena GmbH, Jena, Germany), from now on Panbio test, is a widely used test that detects SARS-CoV-2 viral nucleocapsid protein in biological samples (i.e., nasopharyngeal swabs) (6). Our objective was to assess in real-life the misdiagnosis rate among negative COVID-19 patients with the Panbio test during 2021, where the prevalence of different SARS-CoV-2 variants and the proportion of vaccinated people changed substantially over time. For the analysis, 3657 participants were included, whose characteristics are shown in Table 1 . The median age was 53.6 years, and 46.5% were male. Besides, 24.5% had hypertension, 9.7% diabetes mellitus, 13.4% cardiovascular disease, and 9% chronic pulmonary disease. Concerning COVID-19, 80.6% had symptoms. Throughout 2021, percentages of chronic pulmonary disease and COVID-19 symptoms were significantly different among quarters (p<0.05). The FOR values in all 2021 quarters were around 8%, and we did not find significant differences in FOR values among quarters by univariate analysis (p=0.930; Figure 1A) . We also evaluated these differences by COVID-19 symptoms ( Figure 1B) , but we did not find significant differences. Resuming daily life requires ruling out SARS-CoV-2 infection using tests with a high negative predictive value (5). However, mistakenly ruling out a positive individual can promote SARS-CoV-2 infection. The FOR is the probability that a RADT will give a false-negative result because the test is not sensitive enough. In our study, we found FOR values around 8% (<10%), similar to previously published data for the Panbio test (2, 8) . Besides, FOR values were constant during 2021, not being affected by changes in prevalence, SARS-CoV-2 variants, and vaccination rate in Spain (9) . Our data are relevant since some concerns have been raised regarding the Panbio test performance in the changing scenario of the SARS-CoV-2 pandemic (9) . In Spain, the proportion of people fully vaccinated against COVID-19 increased from 0.18% (January) to 81.9% (December). Likewise, the SARS-CoV-2 Alpha variant was dominant during the first semester of 2021 (77% in March and 45% in June). However, the SARS-CoV-2 Delta variant became dominant at the beginning of July (62%) and reached almost 100% and the end of September (99%). At the end of November, Delta still was 100%. In December, the Omicron variant emerged and became dominant (54%) at the end of the month (9) . In this regard, the appearance of SARS-CoV-2 variants could affect the diagnostic performance of the Panbio test due to changes in altered protein, which is recognized by LFA-specific antibodies (10) . Study limitations include the lack of data for Ct ranges in RT-PCR, the lack of data for COVID- In conclusion, our study shows that the misdiagnosis rate among patients with a negative Panbio test was acceptable and remained stable throughout 2021, despite substantial changes in the COVID-19 prevalence, SARS-CoV-2 variants, and vaccination rate. The authors declare that they have no competing interests. All participants gave their consent before enrollment. The Ethics Committee of Hospital General Universitario Gregorio Marañón approved the study (Ref# 162/20). Not applicable. RT-PCR, reverse transcription polymerase chain reaction. Performance of lateral flow assays for SARS-CoV-2 compared to RT-qPCR Pubmed Central PMCID: PMC8389849 following competing interests: CMD is a member of the Editorial Board of PLOS Medicine Managing the risks of making the wrong diagnosis: First, do no harm Point-of-care COVID-19 diagnostics powered by lateral flow assay Diagnostics for COVID-19: moving from pandemic response to control Rapid antigen tests for the detection of SARS-CoV-2: A narrative review Rapid testing for coronavirus disease 2019 (COVID-19) Performance of Rapid Antigen Tests for COVID-19 Diagnosis: A Systematic Review and Meta-Analysis Published online at OurWorldInData.org. 2020 Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic We thank all the participants: patients who participated in this research and medical, nursing staff and data managers who have participated in the project. The datasets used and analyzed during the current study are available from the corresponding authors upon reasonable request. This study was supported by grants from Instituto de Salud Carlos III (Centro de Investigación Biomédica en Red en Enfermedades Infecciosas (CB21/13/00044)).